title: Cancer immunotherapy and nanomedicine.
abstract: The immune system has the ability to recognize and kill pre-cancer and cancer cells. However, with the immune system's surveillance, the survival tumor cells learn how to escape the immune system after immunoselection. Cancer immunotherapy develops strategies to overcome these problems. Nanomedicine applications in cancer immunotherapy include the nanodiagnostics and nanobiopharmaceuticals. In cancer nanodiagnostics, it looks for specific "molecular signatures" in cancer cells or their microenvironment by using genomics and proteomics. Nanobiopharmaceuticals is the field that studies nanotechnology-based therapeutic agents and drug carriers. DNA, RNA, peptides, proteins and small molecules can all be used as cancer therapies when formulated in nanocarriers. Currently, cancer vaccines are applied in treatments with existing cancer or to prevent the development of cancer in certain high risk individuals. Most of the non-specific immune activation agents include adjuvants which enhance immunogenicity and accelerate and prolong the response of cancer vaccines. The carriers of vaccines, such as viruses and nanoparticles, have also been in clinical studies for many years. This review will discuss the relationships between the tumor and the immune system, and also will include topics covering the strategies used in eliminating tumors by using nanomedicine.
authors.affiliation: Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 1319 Kerr Hall, Chapel Hill, North Carolina 27599, USA.
authors.forename: Wei-Yun
authors.initials: WY
authors.lastname: Sheng
authors.forename: Leaf
authors.initials: L
authors.lastname: Huang
mesh_terms: D056704:Adaptive Immunity; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D004337:Drug Carriers; D023281:Genomics; D006801:Humans; D007113:Immunity, Innate; D007167:Immunotherapy / Q000379:methods; D051379:Mice; D050997:Nanomedicine / Q000379:methods*; D053758:Nanoparticles; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D004337:Drug Carriers
references.citation: J Immunother. 2006 Sep-Oct;29(5):558-68
references.pmid: 16971811
references.citation: Nature. 1992 Mar 12;356(6365):152-4
references.pmid: 1545867
references.citation: J Immunol. 2009 Jul 1;183(1):137-44
references.pmid: 19535620
references.citation: J Control Release. 2000 Mar 1;65(1-2):271-84
references.pmid: 10699287
references.citation: Nature. 1978 Jun 29;273(5665):759-61
references.pmid: 566386
references.citation: J Clin Oncol. 1984 Sep;2(9):1002-5
references.pmid: 6470751
references.citation: J Exp Med. 1982 Apr 1;155(4):1063-74
references.pmid: 6460831
references.citation: Nat Med. 2007 Jan;13(1):54-61
references.pmid: 17187072
references.citation: Nat Med. 1999 Apr;5(4):387-91
references.pmid: 10202926
references.citation: Eur J Immunol. 2002 Mar;32(3):634-43
references.pmid: 11857337
references.citation: Clin Cancer Res. 2002 May;8(5):1028-37
references.pmid: 12006515
references.citation: J Clin Oncol. 2005 Apr 1;23(10):2346-57
references.pmid: 15800326
references.citation: Nat Med. 1998 Mar;4(3):328-32
references.pmid: 9500607
references.citation: Arch Immunol Ther Exp (Warsz). 2006 Sep-Oct;54(5):323-33
references.pmid: 17031467
references.citation: Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3392-7
references.pmid: 12626740
references.citation: Blood. 2002 Mar 1;99(5):1517-26
references.pmid: 11861263
references.citation: Vaccine. 2004 Nov 25;23(2):172-81
references.pmid: 15531034
references.citation: Vaccine. 2004 Jun 23;22(19):2406-12
references.pmid: 15193402
references.citation: Mol Ther. 2003 May;7(5 Pt 1):640-8
references.pmid: 12718907
references.citation: Mol Membr Biol. 2006 Sep-Oct;23(5):385-95
references.pmid: 17060156
references.citation: Semin Oncol. 1986 Sep;13(3 Suppl 2):35-42
references.pmid: 3532334
references.citation: Cancer Res. 2007 Aug 1;67(15):7487-94
references.pmid: 17671219
references.citation: Gene Ther. 1997 Sep;4(9):891-900
references.pmid: 9349425
references.citation: Lancet. 1995 Jun 3;345(8962):1392-7
references.pmid: 7760609
references.citation: J Transl Med. 2009 Dec 10;7:104
references.pmid: 20003308
references.citation: Infect Immun. 1997 May;65(5):1716-21
references.pmid: 9125552
references.citation: J Clin Oncol. 2008 Apr 20;26(12):2034-9
references.pmid: 18347008
references.citation: J Immunol. 2002 Nov 1;169(9):4905-12
references.pmid: 12391202
references.citation: Nat Med. 2001 Oct;7(10):1159-62
references.pmid: 11590442
references.citation: J Pharm Sci. 2008 Sep;97(9):4011-9
references.pmid: 18240304
references.citation: Immunology. 2007 Oct;122(2):149-56
references.pmid: 17848162
references.citation: Nature. 2001 Apr 26;410(6832):1107-11
references.pmid: 11323675
references.citation: Tokai J Exp Clin Med. 1990 Jul;15(4):307-15
references.pmid: 2130538
references.citation: Methods Mol Med. 2002;69:73-81
references.pmid: 11987799
references.citation: Br J Exp Pathol. 1974 Aug;55(4):320-7
references.pmid: 4433467
references.citation: Acta Pharmacol Sin. 2007 May;28(5):695-702
references.pmid: 17439726
references.citation: Cancer Res. 2001 May 1;61(9):3689-97
references.pmid: 11325840
references.citation: Immunol Lett. 2001 Nov 1;79(1-2):97-100
references.pmid: 11595295
references.citation: J Immunother Emphasis Tumor Immunol. 1995 Feb;17(2):71-7
references.pmid: 7647958
references.citation: Nature. 1969 Aug 23;223(5208):844-5
references.pmid: 5799031
references.citation: Int J Cancer. 2002 Aug 20;100(6):690-7
references.pmid: 12209608
references.citation: Cancer Res. 1987 May 1;47(9):2481-5
references.pmid: 3567933
references.citation: Vaccine. 2001 Mar 21;19(17-19):2673-80
references.pmid: 11257408
references.citation: J Immunother. 2000 Mar-Apr;23(2):255-66
references.pmid: 10746552
references.citation: Nat Rev Immunol. 2004 Apr;4(4):249-58
references.pmid: 15057783
references.citation: Nat New Biol. 1972 Mar 22;236(64):78-9
references.pmid: 4502458
references.citation: Cancer Immunol Immunother. 2006 Mar;55(3):320-8
references.pmid: 16133113
references.citation: J Pharm Sci. 1998 Nov;87(11):1421-7
references.pmid: 9811500
references.citation: Ann Neurol. 2000 Jul;48(1):27-38
references.pmid: 10894213
references.citation: J Clin Invest. 2005 Mar;115(3):739-46
references.pmid: 15696196
references.citation: J Immunol. 2006 Dec 15;177(12):8708-13
references.pmid: 17142772
references.citation: Blood. 2000 Nov 1;96(9):3102-8
references.pmid: 11049990
references.citation: Cancer Immunol Immunother. 2005 Dec;54(12):1180-90
references.pmid: 15846491
references.citation: Nat Rev Immunol. 2009 Mar;9(3):162-74
references.pmid: 19197294
references.citation: Nanomedicine (Lond). 2008 Jun;3(3):343-55
references.pmid: 18510429
references.citation: J Immunol Methods. 1986 Jun 24;90(2):221-33
references.pmid: 3722826
references.citation: Cancer Res. 1997 Oct 15;57(20):4557-63
references.pmid: 9377569
references.citation: Cancer Res. 2006 Apr 1;66(7):3859-68
references.pmid: 16585214
references.citation: Int J Cancer. 2002 Mar 10;98(2):221-7
references.pmid: 11857412
references.citation: Cancer Immunol Immunother. 2010 Jan;59(1):137-48
references.pmid: 19590872
references.citation: Med Oncol. 2009;26 Suppl 1:13-7
references.pmid: 19148594
references.citation: Leukemia. 2007 Jan;21(1):53-60
references.pmid: 17066089
references.citation: J Immunol. 1992 Jan 1;148(1):13-8
references.pmid: 1727862
references.citation: Immunology. 1996 Sep;89(1):59-67
references.pmid: 8911141
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7
references.pmid: 12826605
references.citation: Recent Pat Drug Deliv Formul. 2007;1(1):1-9
references.pmid: 19075870
references.citation: J Liposome Res. 2006;16(3):157-66
references.pmid: 16952870
references.citation: Science. 1990 Mar 23;247(4949 Pt 1):1465-8
references.pmid: 1690918
references.citation: J Virol. 2000 Sep;74(18):8700-8
references.pmid: 10954571
references.citation: J Exp Med. 1995 Sep 1;182(3):639-41
references.pmid: 7650475
references.citation: Int J Cancer. 1999 Aug 12;82(4):549-55
references.pmid: 10404069
references.citation: Acta Pharmacol Sin. 2005 Jan;26(1):1-9
references.pmid: 15659107
references.citation: Cancer Res. 2000 Feb 15;60(4):1111-6
references.pmid: 10706132
references.citation: J Immunol. 1980 May;124(5):2436-41
references.pmid: 6154103
references.citation: Am J Obstet Gynecol. 2004 Nov;191(5):1598-605
references.pmid: 15547530
references.citation: J Neuroimmunol. 2008 Mar;195(1-2):21-7
references.pmid: 18304655
references.citation: Vaccine. 2006 Oct 30;24(42-43):6534-41
references.pmid: 16842893
references.citation: Cancer Res. 2008 Jun 1;68(11):4026-30
references.pmid: 18519658
references.citation: Nat Biotechnol. 2007 Oct;25(10):1159-64
references.pmid: 17873867
references.citation: Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):7915-8
references.pmid: 1518813
references.citation: Cancer Immunol Immunother. 2010 May;59(5):759-67
references.pmid: 19943047
references.citation: Vaccine. 2008 Sep 15;26(39):5046-57
references.pmid: 18680779
references.citation: J Exp Med. 1989 Aug 1;170(2):511-26
references.pmid: 2526848
references.citation: Mol Pharm. 2009 Jan-Feb;6(1):211-20
references.pmid: 19072654
references.citation: Int J Oncol. 2003 Mar;22(3):651-6
references.pmid: 12579320
references.citation: Curr Protoc Hum Genet. 2001 May;Chapter 12:Unit 12.8
references.pmid: 18428252
references.citation: Biomaterials. 2009 Jan;30(1):52-7
references.pmid: 18848723
references.citation: J Exp Med. 1990 Jul 1;172(1):231-7
references.pmid: 2193096
references.citation: Curr Mol Med. 2007 Aug;7(5):490-503
references.pmid: 17691964
references.citation: Immunity. 2004 Aug;21(2):137-48
references.pmid: 15308095
references.citation: Ann Surg. 1998 Sep;228(3):307-19
references.pmid: 9742914
references.citation: J Immunol. 2006 May 15;176(10):6347-55
references.pmid: 16670347
references.citation: Adv Drug Deliv Rev. 2001 Sep 23;51(1-3):43-54
references.pmid: 11516778
references.citation: Arch Pharm Res. 2009 May;32(5):781-7
references.pmid: 19471894
references.citation: Br J Cancer. 1985 Jun;51(6):815-26
references.pmid: 3873953
references.citation: Cancer Res. 2002 Dec 1;62(23):6952-8
references.pmid: 12460912
references.citation: Clin Cancer Res. 2008 Mar 15;14(6):1905-12
references.pmid: 18347194
references.citation: Br J Dermatol. 2003 Nov;149 Suppl 66:53-6
references.pmid: 14616352
references.citation: Gynecol Oncol. 2009 May;113(2):210-5
references.pmid: 19264351
references.citation: Cancer Res. 1998 Aug 15;58(16):3660-7
references.pmid: 9721876
references.citation: Clin Cancer Res. 1998 Aug;4(8):2009-14
references.pmid: 9717832
references.citation: Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4265-73
references.pmid: 16857801
references.citation: Adv Drug Deliv Rev. 1998 Apr 6;31(1-2):89-104
references.pmid: 10837619
references.citation: J Exp Med. 1982 Jun 1;155(6):1610-22
references.pmid: 6176663
references.citation: J Intern Med. 2003 Apr;253(4):402-10
references.pmid: 12653868
references.citation: Immunity. 2009 Dec 18;31(6):873-84
references.pmid: 19931471
references.citation: Science. 1993 Mar 19;259(5102):1745-9
references.pmid: 8456302
references.citation: Immunol Rev. 1999 Aug;170:85-100
references.pmid: 10566144
references.citation: J Exp Med. 1991 Jul 1;174(1):139-49
references.pmid: 1711560
references.citation: Infect Immun. 1991 Sep;59(9):2978-86
references.pmid: 1879922
references.citation: J Transl Med. 2009 Jul 20;7:63
references.pmid: 19619321
references.citation: J Clin Invest. 2001 Sep;108(5):669-78
references.pmid: 11544272
references.citation: Mol Ther. 2003 Apr;7(4):498-505
references.pmid: 12727113
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4456-66
references.pmid: 17671130
references.citation: Gynecol Oncol. 2008 May;109(2):174-81
references.pmid: 18314182
references.citation: J Control Release. 2006 May 1;112(1):26-34
references.pmid: 16529839
references.citation: Neuro Oncol. 2006 Jan;8(1):60-6
references.pmid: 16443949
references.citation: Ann Oncol. 2006 Apr;17(4):563-70
references.pmid: 16418308
references.citation: Adv Drug Deliv Rev. 2000 Mar 30;41(2):171-88
references.pmid: 10699313
references.citation: Clin Exp Immunol. 2006 Apr;144(1):41-7
references.pmid: 16542363
references.citation: Cancer Immunol Immunother. 2008 Apr;57(4):517-30
references.pmid: 17724588
references.citation: Adv Enzyme Regul. 2001;41:189-207
references.pmid: 11384745
references.citation: Hum Gene Ther. 1999 Sep 1;10(13):2153-61
references.pmid: 10498247
references.citation: Expert Opin Drug Deliv. 2008 Sep;5(9):979-1001
references.pmid: 18754749
references.citation: Biochemistry. 1996 Jan 23;35(3):1027-36
references.pmid: 8547238
references.citation: BMC Neurosci. 2008 Dec 10;9 Suppl 3:S4
references.pmid: 19091001
references.citation: J Immunother. 2007 May-Jun;30(4):378-95
references.pmid: 17457213
references.citation: Vaccine. 2008 Sep 2;26(37):4866-75
references.pmid: 18455278
references.citation: Mol Immunol. 2007 Jul;44(15):3672-81
references.pmid: 17521728
references.citation: Oncology (Williston Park). 2002 Nov;16(11 Suppl 13):11-20
references.pmid: 12469935
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18264-8
references.pmid: 16344458
references.citation: Vaccine. 2008 Mar 4;26(10):1303-13
references.pmid: 18255205
references.citation: Br J Cancer. 2000 Mar;82(6):1138-44
references.pmid: 10735496
references.citation: J Parenter Sci Technol. 1992 Sep-Oct;46(5):176-80
references.pmid: 1331390
references.citation: Cancer Immunol Immunother. 2007 May;56(5):641-8
references.pmid: 16960692
references.citation: Curr Opin Pharmacol. 2009 Aug;9(4):470-81
references.pmid: 19616475
references.citation: Biotherapy. 1992;5(4):275-80
references.pmid: 1290723
references.citation: Vaccine. 2000 Nov 22;19(7-8):764-78
references.pmid: 11115698
references.citation: Annu Rev Immunol. 2004;22:329-60
references.pmid: 15032581
references.citation: Front Biosci. 2002 May 01;7:e204-13
references.pmid: 11991853
references.citation: Mol Pharm. 2008 Jul-Aug;5(4):496-504
references.pmid: 18611037
references.citation: Expert Opin Drug Deliv. 2008 Jul;5(7):789-803
references.pmid: 18590463
references.citation: Mol Ther. 2001 May;3(5 Pt 1):673-82
references.pmid: 11356072
references.citation: Clin Cancer Res. 2003 Jul;9(7):2487-96
references.pmid: 12855622
references.citation: J Natl Cancer Inst. 1970 Aug;45(2):365-76
references.pmid: 5514991
references.citation: J Immunol. 2003 Mar 1;170(5):2523-30
references.pmid: 12594278
references.citation: Science. 1994 May 13;264(5161):961-5
references.pmid: 7513904
references.citation: Cancer. 2007 Jul 1;110(1):103-11
references.pmid: 17516438
references.citation: Science. 2005 Aug 26;309(5739):1380-4
references.pmid: 16123302
references.citation: J Immunol Methods. 1993 Mar 15;160(1):49-57
references.pmid: 7680698
references.citation: Vaccine. 2009 May 26;27(25-26):3331-4
references.pmid: 19200813
references.citation: Clin Cancer Res. 2007 Oct 15;13(20):6168-74
references.pmid: 17947483
references.citation: Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1522-8
references.pmid: 16884360
references.citation: Nat Med. 1998 Mar;4(3):321-7
references.pmid: 9500606
references.citation: J Drug Target. 1996;3(5):317-9
references.pmid: 8866651
references.citation: Oncology. 2004;66(5):343-6
references.pmid: 15331919
references.citation: Clin Cancer Res. 2000 Jun;6(6):2268-78
references.pmid: 10873077
references.citation: Int J Cancer. 1996 Nov 27;68(5):629-36
references.pmid: 8938146
references.citation: Clin Cancer Res. 2008 Jun 1;14(11):3462-9
references.pmid: 18519778
references.citation: Pharm Res. 2004 Jun;21(6):1018-25
references.pmid: 15212168